CN114058636A - Method for cloning, expressing and purifying transthyretin gene - Google Patents
Method for cloning, expressing and purifying transthyretin gene Download PDFInfo
- Publication number
- CN114058636A CN114058636A CN202111358279.7A CN202111358279A CN114058636A CN 114058636 A CN114058636 A CN 114058636A CN 202111358279 A CN202111358279 A CN 202111358279A CN 114058636 A CN114058636 A CN 114058636A
- Authority
- CN
- China
- Prior art keywords
- ttr
- protein
- buffer
- anion exchange
- purified
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
Abstract
The invention discloses a method for cloning, expressing and purifying TTR gene, which comprises the steps of obtaining TTR recombinant plasmid by chemical synthesis and double enzyme digestion, inducing protein to express in large quantity, salting out, buffer solution replacement dialysis, anion exchange column and gel filtration chromatography column to obtain TTR protein with purified precision. The protein purification method is based on an AKTA protein purification system, is simple and convenient to operate, can simultaneously realize automatic washing, online monitoring, real-time observation and the like of a sample, can adjust the purification process in time according to the condition of the sample and the subsequent requirement on the purified sample, obtains the TTR protein with high purity, can save precious plasma resources to the maximum extent, and simultaneously lays a foundation for the in vitro research of TTR genes in future.
Description
Technical Field
The invention belongs to the technical field of biology, and particularly relates to a method for cloning, prokaryotic expression and protein purification of a transthyretin (TTR) gene.
Technical Field
Transthyretin (TTR), also known as Prealbumin (PA), is a tetrameric protein formed by 4 identical subunits connected by non-covalent bonds, each subunit consisting of 127 amino acids and having a relative molecular mass of 55 kDa. In vivo, TTR is produced primarily by the choroid plexus of the liver and brain, and also is synthesized in small amounts by retinal epithelial cells, primarily in blood and cerebrospinal fluid, at levels of about 3.4-5. mu. mol/L in blood and about 0.04-0.4. mu. mol/L in cerebrospinal fluid. The protein has the main physiological functions of transferring thyroxine and transferring vitamin A by combining with retinol binding protein.
Under normal physiological conditions, TTR functions as a stable tetramer, but when a gene coding for TTR is mutated or grows with age, the protein tetramer structure of TTR is unstable, TTR monomer pathologically aggregates in tissues such as peripheral nervous system, heart, eye, kidney, meninges and the like to form insoluble amyloid deposition, and transthyretin Amyloidosis (ATTR) disease is caused. Research reports that ATTR diseases have the characteristics of low morbidity, progressive exacerbation, various clinical manifestations, great difficulty in clinical diagnosis and differential diagnosis and the like, the survival period of patients after confirmed diagnosis is only 2-12 years generally, and most of patients can die from heart diseases.
Currently, in clinical treatment of ATTR disease, liver transplantation has become the first line of treatment, and not only can the variant TTR be reduced, but also the overall survival rate can be improved. However, liver transplantation has the effects of donor shortage, operation risk, acute rejection, long-term use of immunosuppressive agents, patient condition limitation and the like. In recent years, given the increasing maturity of protein expression and purification techniques and protein stability research techniques, more and more research teams have focused therapeutic strategies for ATTR disease on inhibiting the dissociation of TTR tetramers, i.e. slowing the rate of amyloid formation. Therefore, the efficient purification scheme of the TTR protein has significant practical significance and application value for the research and treatment of diseases.
At present, the reported TTR protein extraction and purification methods (EP0711786a2, US5310878a1) disclose a method for purifying human plasma prealbumin, which requires 11 extraction steps including ion exchange, immunodiffusion, affinity chromatography, size exclusion chromatography, and multiple buffer replacement and concentration steps under specific conditions. In addition, CN103833843A discloses a method for extracting and purifying prealbumin PA from normal human plasma, which requires solution extraction, buffer solution replacement dialysis, and purification of three kinds of chromatographic columns in AKTA system. The methods directly extract and purify TTR protein from human plasma, and have the disadvantages of complicated steps and complex operation, thus being difficult to meet the requirements of industrial production or clinical research.
Disclosure of Invention
In view of the limitation of the existing TTR protein purification, the invention provides a brand new TTR purification method, which comprises the steps of obtaining TTR recombinant plasmids by chemical synthesis and double enzyme digestion, inducing protein to express in large quantity, primarily purifying TTR protein by salting out, buffer solution replacement dialysis, anion exchange column and other steps, and finally obtaining highly purified TTR protein by matching with a gel filtration chromatographic column. The establishment of the method not only greatly saves precious plasma resources, but also greatly promotes the development of relevant research on pathogenesis and treatment of ATTR diseases.
In order to achieve the technical effects, the invention specifically provides the following technical scheme:
in a first aspect of the present invention, there is provided a method for cloning, expressing, isolating and purifying transthyretin (TTR), the method comprising the steps of:
(1) cloning of TTR gene:
NdeI-TTR-Xho I sequence is designed and PCR amplified through splicing chemically synthesized and purified TTR gene vector. Preferably, the nucleotide sequence of the Nde I-TTR-Xho I sequence is shown in SEQ ID NO. 1.
(2) Construction of recombinant expression plasmids:
digesting the expression vector by using restriction enzyme, inserting the TTR coding sequence into the corresponding site of the vector to obtain the recombinant expression plasmid.
(3) Expression and purification of TTR protein:
culturing competent BL21(DE3) transferred into recombinant expression plasmid at 37 deg.C, adding IPTG to induce protein expression, performing ultrasonic cell disruption, salting out and dialysis, and purifying TTR protein with strong anion exchange chromatography column and gel filtration chromatography column.
In one embodiment, in step (1), the cleavage sites at the N-terminus and C-terminus are NdeI and Xho I, respectively.
In one embodiment, the chemically synthesized TTR gene fragment is 396bp in length.
In one embodiment, in step (2), the expression vector is pET-29b (+).
In one embodiment, in step (3), the concentration of IPTG is 0.2-2 mM.
In one embodiment, in step (3), the conditions for ultrasonic cell disruption are 100-200W, 1s, and 5 s; the bacterial lysate was 50mM Tris, 150mM NaCl, pH 7.5.
In one embodiment, in step (3), the agent used for salting out is ammonium sulfate.
In one embodiment, in step (3), the conditions of the strong anion exchange chromatography column and the buffer are as follows:
a chromatographic column: 50mL Source 15Q.
Anion exchange buffer a: 25mM Tris, 1mM EDTA, pH 8.0.
Elution buffer B: 350mM NaCl.
In one embodiment, in step (3), the conditions for purifying TTR protein by strong anion exchange chromatography are: washing the chromatographic column by 50mL of solution A; solution B was eluted with a linear gradient (160mL, 50-350mM) followed by washing with solution B.
In one embodiment, in step (3), the gel filtration chromatography column and the buffer are under the following conditions:
a chromatographic column: 120mL Superdex 200.
SEC buffer: 10mM sodium phosphate, 100mM KCl, 1mM EDTA, pH 7.4.
In one embodiment, in step (3), the conditions for purifying TTR protein by gel filtration chromatography are: elution flow rate was 1mL/min, SEC buffer elution volume 120 mL.
Compared with the prior art, the invention has the following beneficial technical effects:
(1) establishing a prokaryotic gene expression system capable of being used for expressing TTR protein in a large quantity;
(2) by utilizing the salting-out characteristic of the protein, the foreign protein is greatly reduced through twice precipitation purification;
(3) based on the AKTA protein purification system, the method is simple and convenient to operate, simultaneously realizes multiple steps of automatic washing, online monitoring, real-time observation and the like of the sample, and can adjust the purification process in time according to the sample condition and the subsequent requirement on the purified sample.
Drawings
FIG. 1 Strong anion exchange chromatography purification of TTR profile;
FIG. 2 gel filtration chromatography purification of TTR profile;
FIG. 3 is a graph showing the electrophoresis results of purified TTR protein; wherein, from left to right, the channel 1 is a protein Marker; the channel 2 is a sample after strong anion exchange chromatography purification; the channel 3 is a sample after gel filtration chromatography purification;
FIG. 4UPLC purity test;
FIG. 5 molecular weight size of TTR by mass spectrometry;
FIG. 6 is a graphical representation of the results of tetrameric TTR protein activity.
Detailed Description
The invention will now be further described with reference to the following examples, which are intended to be illustrative of the invention and are not to be construed as limiting the invention.
The experimental procedures used in the following examples are conventional ones without specific mention.
The test consumables used in the examples described below were commercially available without specific reference.
Example 1: construction of recombinant cloning vector Nde I-TTR-Xho I
Primer design for TTR
Using pET-29b (+) as a template, designing an NdeI-TTR-Xho I sequence by splicing a chemically synthesized and purified TTR gene vector, and performing PCR amplification, wherein the nucleotide sequence of the NdeI-TTR-Xho I sequence is shown in SEQ ID NO:1 and consists of an endonuclease site NdeI-TTR protein coding sequence-an endonuclease site Xho I.
NdeI-TTR-Xho I is cloned and connected with digested pET-29b (+) plasmid template
mu.L of Nde I-TTR-Xho I was taken, 2. mu.L of digested pET-29b (+) plasmid template was added, 5. mu.L of ligation buffer and 2. mu.L of sterile water were added to 10. mu.L of the system, and ligation was performed at 16 ℃ for 2 hours.
Cloning and transformation of pET-29b (+) -TTR plasmid template
Transferring 2 mu L of the ligation product to 50 mu LDH5 alpha competent cells, and standing for 30min on ice; heat shock is carried out for 45s at 42 ℃; standing on ice for 5 min; adding 450 μ L LB (Tryptone 10g/L, Yeast extract 5g/L, NaCl 10g/L, pH 7.5), shaking at 37 deg.C and 220rpm for 1 h; centrifuging at 4000rpm for 3 min; most of the supernatant was removed in a clean bench, the pellet was gently suspended, and plated on LB plate containing 50. mu.g/mL kanamycin (Kan); the LB plate was placed upside down in a 37 ℃ incubator overnight.
Identification of clone pET-29b (+) -TTR
Randomly selecting 4 positive clones, and inoculating the positive clones into 4mL LB (Kan +); shaking overnight at 220rpm with a shaker at 37 ℃; plasmid pET-29b (+) -TTR was extracted, stored at-80 ℃ and plasmid sequencing was performed with primer T7.
Example 2: construction of recombinant expression plasmid pET-29b (+) -TTR
1. Digestion and recovery
Nde I and Xho I restriction sites are added into the TTR gene sequence, Nde I-TTR-Xho I and pET-29b (+) plasmid are subjected to double digestion by using Nde I and Xho I, electrophoresis is carried out by using 1% agarose gel, and the target fragment is recovered by using gel.
T4 DNA ligase ligation and transformation
The connecting system is as follows: mu.L of 10 Xligase buffer, 1. mu.L of 10-double-digested pET-29b (+) plasmid, 7. mu.L of Nde I-TTR-Xho I fragment, 1. mu. L T4 DNA ligase, were ligated overnight at 16 ℃.
The ligation products were transformed into DH 5. alpha. competence, transformed, plated on LB plates containing 50. mu.g/mL kanamycin (Kan), and cultured overnight at 37 ℃ in an inverted state.
3. Positive clone identification
Randomly selecting 4 positive clones, and inoculating the positive clones into 4mL LB (Kan +); shaking overnight at 220rpm with a shaker at 37 ℃; the plasmids were extracted for T7 primer-directed plasmid sequencing.
Example 3: inducible expression of TTR protein
1. Materials and reagents
Kanamycin: biyun Tian, China
Isopropyl thiogalactoside: biyun Tian, China
2. Instruments and devices:
an incubator: thermo, USA
UV-5100 ultraviolet visible light breadth meter: shanghai non-analytic Instrument Co., Ltd, China
3. The experimental steps are as follows:
(1) recombinant plasmid transformed Escherichia coli
The recombinant plasmid pET-29b (+) -TTR was transformed into competent BL21(DE3), spread on LB plate containing kanamycin (Kan), and cultured overnight at 37 ℃ in an inverted state.
(2) Isopropyl thiogalactoside (IPTG) induced protein expression
Selecting a single colony of the recombinant strain, inoculating the single colony in LB (Kan +), culturing overnight by a shaking table at 37 ℃ and at 220 rpm; inoculating 2L LB (Kan +) at a ratio of 1:20-40, shaking at 37 deg.C and culturing at 220rpm to OD600nmWhen 0.6-0.8 was reached, IPTG (0.2-2mM) was added to induce protein expression.
Example 4: purification and identification of TTR protein
1. Materials and reagents
Tris (Tris): biyun Tian, China
EDTA: biyun Tian, China
NaCl: xiong science Inc., China
Coomassie brilliant blue G250: biyun Tian, China
2. Instruments and devices:
a pH meter: MettlerToledo, Switzerland
Low-temperature freezing centrifuge: thermo, USA
Ultrasonic cell crusher: ningbo Xinzhi Biotech GmbH, China
A magnetic stirrer: darongxing laboratory instruments Ltd, China
Protein purification instrument: AKTA, USA
Electrophoresis apparatus: beijing, six Biotechnology Ltd, China
AB Sciex 5800MALDI-TOF/TOFTMAppearance: AB SCIEX, USA
A multifunctional microplate reader: tecan, Switzerland
Inducible expression of TTR protein
Selecting a single colony of the recombinant strain, inoculating the single colony in LB (Kan +), culturing overnight by a shaking table at 37 ℃ and at 220 rpm; inoculating 2L LB (Kan +) at a ratio of 1:20-40, shaking at 37 deg.C and culturing at 220rpm to OD600nmWhen 0.6-0.8 was reached, IPTG (0.2-2mM) was added to induce protein expression.
Centrifugation is carried out for 30min at 4 ℃ and 4000g, the supernatant is discarded, and the precipitate is suspended by bacterial lysate.
4. Cell disruption, salting out and dialysis
And (3) fully cracking the bacterial liquid by ultrasonic waves, and then centrifuging the crushed bacterial liquid in a centrifuge at the rotation speed of 16000g for 30min at 4 ℃. The precipitate was discarded and the supernatant was salted out with ammonium sulfate. Finally, the pellet after centrifugation was suspended in 40mL of anion exchange buffer A (25mM Tris, 1mM EDTA, pH 8.0) and dialyzed against buffer A overnight at 4 ℃.
5. Purification of TTR by strong anion exchange chromatography
50mL Source 15Q Strong anion exchange chromatography: solution A (25mM Tris, 1mM EDTA, pH 8.0), solution B (350mM NaCl); after the purified fraction is pumped into the column, it is first subjected to AKTATMThe column was washed off non-specifically adsorbed contaminating proteins by washing the column with 50mL of solution A on a fast protein chromatograph purifactor 100 system, which was then programmed to perform a linear gradient elution with solution B (160mL, 50-350mM) followed by a wash with solution B (50mL, 350 mM). The eluting peak contains TTR, collecting absorption peak II, i.e. about 25mL of TTR eluent, discarding peak I, and the map result is shown in figure 1. Samples were taken for SDS-PAGE and the results are shown in FIG. 3.
6. Purification of TTR by gel filtration chromatography
7. Identification of purity of purified TTR
SDS-PAGE gel electrophoresis through laser gray scanner determination of its purity to reach 99% and above, and show that purified TTR protein monomer molecular mass is about 14kDa, the result is shown in figure 3. In addition, the purity identification result of UPLC is also shown as a single peak, the result is shown in fig. 4, and the purity of TTR protein can be up to 99.5% by calculating the percentage of peak area.
Molecular weight size analysis of TTR
The TTR protein end product obtained in this example was desalted and then passed through AB Sciex 5800MALDI-TOF/TOFTMMass spectrometer detection to determine the molecular weight showed that the molecular weight of the purified TTR protein was about 14kDa as shown in FIG. 5. Consistent with the results of the molecular weight of the monomeric TTR on SDS-PAGE.
9. Activity assay of purified TTR protein
To perform activity analysis on purified TTR protein, the final product TTR protein was first prepared as solutions of different concentration gradients, i.e. 0, 0.5, 1, 2.5, 5, 10 μ M, to which a quantitative amount of fluorescent small molecule a2(S- (4-fluorophenyl) (E) -3- (dimethylamino) -5- (4-hydroxy-3, 5-dimethyltryptyl) thionate) bound only to tetrameric TTR was added, respectively [ Choi S, one DS, Kelly JW. "organic thin selective to transthytin in cells and remains dark units a chemical reaction to yield fluorescent antibody fluorescent protein complex" j.am. chem.2010; 132:16043-16051]Incubation was performed followed by monitoring the fluorescence of the a2 modified TTR conjugate using excitation light at 328nm and emission light at 430nm, with 3 duplicate wells per concentration. And finally, establishing a linear regression model by taking the tetramer TTR concentration as an abscissa and the TTR conjugate fluorescence intensity as an ordinate. The results show that all points fall on the linear regression trend line, and R20.9989, and the two have higher linear relation, which indicates that the purified tetrameric TTR protein has extremely high activity.
It should be understood that the above-mentioned embodiments are merely preferred embodiments of the present invention, and are not intended to limit the scope of the present invention, and any modifications, equivalent substitutions, improvements, etc. made within the spirit and principle of the present invention should be included in the protection scope of the present invention.
SEQ ID NO:1
CATATGGGTCCTACGGGCACCGGTGAATCCAAGTGTCCTCTGATGGTCAAAGTTCTAGATGCTGTCCGAGGCAGTCCTGCCATCAATGTGGCCGTGCATGTGTTCAGAAAGGCTGCTGATGACACCTGGGAGCCATTTGCCTCTGGGAAAACCAGTGAGTCTGGAGAGCTGCATGGGCTCACAACTGAGGAGGAATTTGTAGAAGGGATATACAAAGTGGAAATAGACACCAAATCTTACTGGAAGGCACTTGGCATCTCCCCATTCCATGAGCATGCAGAGGTGGTATTCACAGCCAACGACTCCGGCCCCCGCCGCTACACCATTGCCGCCCTGCTGAGCCCCTACTCCTATTCCACCACGGCTGTCGTCACCAATCCCAAGGAATGACTCGAG
Sequence listing
<110> Dalian run-on Kangtai medical laboratory Co., Ltd
<120> method for cloning, expressing and purifying transthyretin gene
<130> CP211042
<141> 2021-11-16
<160> 1
<170> SIPOSequenceListing 1.0
<210> 1
<211> 396
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 1
catatgggtc ctacgggcac cggtgaatcc aagtgtcctc tgatggtcaa agttctagat 60
gctgtccgag gcagtcctgc catcaatgtg gccgtgcatg tgttcagaaa ggctgctgat 120
gacacctggg agccatttgc ctctgggaaa accagtgagt ctggagagct gcatgggctc 180
acaactgagg aggaatttgt agaagggata tacaaagtgg aaatagacac caaatcttac 240
tggaaggcac ttggcatctc cccattccat gagcatgcag aggtggtatt cacagccaac 300
gactccggcc cccgccgcta caccattgcc gccctgctga gcccctactc ctattccacc 360
acggctgtcg tcaccaatcc caaggaatga ctcgag 396
Claims (10)
1. A transthyretin gene (TTR) cloning, expression and protein purification method is characterized by comprising the following steps:
(1) cloning of TTR gene:
NdeI-TTR-Xho I sequence is designed and PCR amplified through splicing chemically synthesized and purified TTR gene vector.
(2) Construction of recombinant expression plasmids:
digesting the expression vector by using restriction enzyme, inserting the TTR coding sequence into the corresponding site of the vector to obtain the recombinant expression plasmid.
(3) Expression and purification of TTR protein:
BL21(DE3) competent Escherichia coli transferred with the recombinant expression plasmid is cultured at 37 ℃, IPTG is added to induce protein expression, then ultrasonic cell disruption, salting out and dialysis are carried out, and TTR protein is purified by a strong anion exchange chromatographic column and a gel filtration chromatographic column.
2. The method according to claim 1, wherein the Nde I-TTR-Xho I sequence is as shown in SEQ ID NO 1.
3. The method of claim 1, wherein in step (2), the vector is pET-29b (+).
4. The method of claim 1, wherein in step (3), the concentration of IPTG is 0.2-2 mM.
5. The method as claimed in claim 1, wherein in the step (3), the conditions for the ultrasonic cell disruption are 100-200W, 1s and 5 s; the bacterial lysate was 50mM Tris, 150mM NaCl, pH 7.5.
6. The method according to claim 1, wherein in the step (3), the agent for salting out is ammonium sulfate.
7. The method of claim 1, wherein the strong anion exchange chromatography column and the buffer are under the following conditions:
a chromatographic column: 50mL Source 15Q;
anion exchange buffer a: 25mM Tris, 1mM EDTA, pH 8.0.
Elution buffer B: 350mM NaCl.
8. The method of claim 1, wherein in step (3), the conditions for purifying TTR protein by strong anion exchange chromatography are as follows: washing the chromatographic column by 50mL of solution A; and (3) carrying out linear gradient elution on the solution B under the elution condition of 160mL and 50-350mM, and then washing with the solution B.
9. The method of claim 1, wherein the gel filtration chromatography column and buffer conditions are as follows:
a chromatographic column: 120mL Superdex 200.
Buffer solution: 10mM sodium phosphate, 100mM KCl, 1mM EDTA, pH 7.4, the buffer is SEC buffer.
10. The method of claim 1, wherein in step (3), the conditions for purifying TTR protein by gel filtration chromatography are as follows: elution flow rate was 1mL/min, SEC buffer elution volume 120 mL.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111358279.7A CN114058636A (en) | 2021-11-16 | 2021-11-16 | Method for cloning, expressing and purifying transthyretin gene |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111358279.7A CN114058636A (en) | 2021-11-16 | 2021-11-16 | Method for cloning, expressing and purifying transthyretin gene |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114058636A true CN114058636A (en) | 2022-02-18 |
Family
ID=80272808
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111358279.7A Pending CN114058636A (en) | 2021-11-16 | 2021-11-16 | Method for cloning, expressing and purifying transthyretin gene |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114058636A (en) |
Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5310878A (en) * | 1992-10-23 | 1994-05-10 | Baxter Diagnostics Inc. | Biosynthetic cerebrospinal fluid control and method of use |
| EP0711786A2 (en) * | 1991-03-07 | 1996-05-15 | Dade International Inc. | Purifying prealbumin |
| WO1999016889A1 (en) * | 1997-10-01 | 1999-04-08 | G.D. Searle & Co. | Fusion proteins comprising an angiostatin moiety and their use in anti-tumor treatment |
| US20100120893A1 (en) * | 2008-10-20 | 2010-05-13 | Dinah Wen-Yee Sah | Compositions and Methods for Inhibiting Expression of Transthyretin |
| US20110237646A1 (en) * | 2008-08-07 | 2011-09-29 | Isis Pharmaceuticals, Inc. | Modulation of transthyretin expression for the treatment of cns related disorders |
| CN103038345A (en) * | 2010-04-29 | 2013-04-10 | Isis制药公司 | Modulation of transthyretin expression |
| CN103833843A (en) * | 2012-11-27 | 2014-06-04 | 上海复星医药（集团）股份有限公司 | Method for extracting and purifying prealbumin PA from plasma of normal people |
| CN106255702A (en) * | 2013-12-20 | 2016-12-21 | 生物控股有限公司 | The therapy to transthyretin (TTR) amyloidosis based on antibody and human antibody thereof |
| CN110960687A (en) * | 2019-12-17 | 2020-04-07 | 上海卡序生物医药科技有限公司 | Application of transthyretin for transferring fusion protein into eyes |
| CN111875692A (en) * | 2019-10-30 | 2020-11-03 | 南京理工大学 | Rare crucian transthyretin protein gene, protein sequence and application thereof |
-
2021
- 2021-11-16 CN CN202111358279.7A patent/CN114058636A/en active Pending
Patent Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0711786A2 (en) * | 1991-03-07 | 1996-05-15 | Dade International Inc. | Purifying prealbumin |
| US5310878A (en) * | 1992-10-23 | 1994-05-10 | Baxter Diagnostics Inc. | Biosynthetic cerebrospinal fluid control and method of use |
| WO1999016889A1 (en) * | 1997-10-01 | 1999-04-08 | G.D. Searle & Co. | Fusion proteins comprising an angiostatin moiety and their use in anti-tumor treatment |
| US20110237646A1 (en) * | 2008-08-07 | 2011-09-29 | Isis Pharmaceuticals, Inc. | Modulation of transthyretin expression for the treatment of cns related disorders |
| US20100120893A1 (en) * | 2008-10-20 | 2010-05-13 | Dinah Wen-Yee Sah | Compositions and Methods for Inhibiting Expression of Transthyretin |
| CN103038345A (en) * | 2010-04-29 | 2013-04-10 | Isis制药公司 | Modulation of transthyretin expression |
| CN103833843A (en) * | 2012-11-27 | 2014-06-04 | 上海复星医药（集团）股份有限公司 | Method for extracting and purifying prealbumin PA from plasma of normal people |
| CN106255702A (en) * | 2013-12-20 | 2016-12-21 | 生物控股有限公司 | The therapy to transthyretin (TTR) amyloidosis based on antibody and human antibody thereof |
| CN111875692A (en) * | 2019-10-30 | 2020-11-03 | 南京理工大学 | Rare crucian transthyretin protein gene, protein sequence and application thereof |
| CN110960687A (en) * | 2019-12-17 | 2020-04-07 | 上海卡序生物医药科技有限公司 | Application of transthyretin for transferring fusion protein into eyes |
Non-Patent Citations (2)
| Title |
|---|
| 李钧敏等: "人血浆转甲状腺素蛋白的提纯及其对肝癌细胞生长的抑制作用", 《中国肿瘤生物治疗杂志》, vol. 6, no. 2, 30 June 1999 (1999-06-30), pages 97 - 101 * |
| 胡城: "转甲状腺素蛋白野生型及其V30A、V30M突变体的表达、纯化和稳定性研究", 《中国优秀博硕士学位论文全文数据库(硕士)基础科学辑》, no. 09, 15 September 2013 (2013-09-15), pages 006 - 29 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1874932B1 (en) | Production of recombinant proteins by autoproteolytic cleavage of a fusion protein | |
| CN110305224B (en) | Abeta 42 modified protein with protein aggregation resistance function and expression and purification method thereof | |
| CN114058636A (en) | Method for cloning, expressing and purifying transthyretin gene | |
| CN112175980B (en) | Method for improving activity of polymerase large fragment through site-directed mutagenesis and application | |
| JP2019518787A (en) | Method for affinity purification of recombinant proteins based on lectin activity of galectin CRD | |
| CN107746432B (en) | A β 42 modified protein and expression and purification method thereof | |
| TWI531578B (en) | Solubility enhancing peptide and use thereof | |
| CN108841846B (en) | Recombinant fluorescent protein with large Stokes shift and preparation method thereof | |
| CN111116757A (en) | Ferritin fusion protein with galactose-binding lectin EW29 label, protein cage nanoparticles and preparation method thereof | |
| CN102127156A (en) | Fusion tagging protein for nonchromatographic sepration of target protein and coding gene and preparation method thereof | |
| TWI712691B (en) | Dextran affinity tag and application thereof | |
| RU2816486C2 (en) | Chimeric enzyme mgl-s3 - methionine-gamma-lyase fused with s3 domain of vgf protein from vaccinia virus, method for producing mgl-s3 and anticancer preparation based on this enzyme | |
| CN115896048B (en) | Recombinant human Cu, zn-SOD with high enzyme activity and good stability, and preparation method and application thereof | |
| US11248217B2 (en) | Engineered carbohydrate-active enzymes for glycan polymers synthesis | |
| WO2008089690A1 (en) | Preparation process of recombinant human p43 protein | |
| CN116355071A (en) | Expression and purification method of WTX and truncate recombinant protein thereof and application of WTX and truncate recombinant protein in phase separation experiment | |
| Hasan et al. | Partial purification of topoisomerase IB from serum of diabetic patients and study it's kinetic properties and molecular weight | |
| CN115851748A (en) | Preparation method and application of beta 2-MG truncation | |
| KR101841646B1 (en) | Method for the preparation of AIMP2-DX2 as a target for anti-cancer drug discovery | |
| CN106279428A (en) | There is antagonist protein CBD-PlexinB1LBD and the application of the neuranagenesis Inhibitory molecules of collagen specificity binding ability | |
| CN116284410A (en) | Method for purifying HER2 single-chain antibody | |
| CN117431232A (en) | Recombinant Taq DNA polymerase, and preparation method and application thereof | |
| Werther et al. | Glutamic acid-modified classical swine fever virus autoproteases N pro | |
| JP2023094202A (en) | Method for cyclizing and purifying target protein from fusion protein including target protein, method for producing cyclized target protein from fusion protein including target protein, and fusion protein to be used for cyclizing and purifying target protein | |
| CN115873811A (en) | PBCV-1 ligase mutant, expression and purification method and application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20221111 Address after: 116001 No. 1 (- 4), Floor 4, No. 11A, Yuguang Street, Zhongshan District, Dalian, Liaoning Applicant after: Dalian Boyuan Medical Technology Co.,Ltd. Address before: 3 / F, No. 300-8, jinlongsi Road, Ganjingzi District, Dalian City, Liaoning Province, 116033 Applicant before: Dalian Runsheng Kangtai Medical Laboratory Co.,Ltd. |
|
| TA01 | Transfer of patent application right |